Arbutus Biopharma (ABUS) Earnings Analysis
Arbutus Biopharma (ABUS) has no confirmed upcoming earnings date. Last quarter (2026-03-23) it beat with EPS -0.01 USD vs -0.03505 USD est (+71.5%). It has beaten estimates in 2/4 recent quarters (50%). Trailing P/E 5.19.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ABUS next report earnings?
No confirmed upcoming earnings date is currently scheduled for ABUS. This page updates as the calendar is published.
ABUS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-23 | -0.01 USD | -0.03505 USD | +71.5% | Beat |
| 2025-11-13 | -0.04 USD | -0.056 USD | +28.6% | Beat |
| 2025-05-14 | -0.13 USD | -0.09 USD | -44.4% | Miss |
| 2024-08-01 | -0.11 USD | -0.1 USD | -10% | Miss |
Beat rate: 2/4 (50%) over reported quarters with consensus data.
ABUS valuation and analyst view
| Trailing P/E | 5.19 |
|---|---|
| Trailing EPS | 0.82944 USD |
| Price / book | 3.22 |
| Dividend yield | 0.00% |
| Market cap | 0.86B |
| Analyst consensus | Buy (8 buy / 2 hold / 0 sell) |
Related research pages
Frequently asked questions
When is Arbutus Biopharma (ABUS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for ABUS. This page updates as the calendar is published.
Did ABUS beat earnings last quarter?
In its 2026-03-23 report, ABUS posted EPS of -0.01 USD versus a -0.03505 USD estimate — a beat of 71.5%.
What is ABUS's earnings track record?
Over the last 4 reported quarters with consensus data, ABUS beat estimates 2 times (50%).
What is ABUS's current P/E ratio and EPS?
ABUS trades at a trailing P/E of 5.19 on trailing EPS of 0.8294427786176195 USD.
What do analysts rate ABUS?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell).